Numinus Wellness To Collaborate With MAPS On Proposed MDMA-Assisted Psychotherapy Trials

Numinus Wellness (TSXV: NUMI) this morning announced that it has entered into an arrangement with a subsidiary of the Multidisciplinary Association for Psychedelic Studies, also known as MAPS, to collaborate on a clinical trial that uses MDMA. The collaboration will see the duo collaborate for Health Canada approval to conduct an MDMA-assisted psychotherapy for PTSD through clinical trials.

Click here to read more.